Schizophrenia
Schizophrenia Day 1: 1 mg PO q12hr; increase qDay to effective dose of 6-12 mg PO q12hr Day 2: 2 mg PO q12hr, THEN increase qDay by 2 mg/day to effective dose of 6-12 mg PO q12hr; not to exceed 24 mg/day Must gradually increase dose to avoid orthostatic hypotension Hepatic impairment Mild: No dosage adjustment required Moderate: Caution advised Severe: Use not recommended
Safety and efficacy not established
Renal impairment: Unlikely to have a significant impact since <1% of drug is excreted unchanged in urine
Hypersensitivity.
May act by antagonizing a combination of dopamine type 2 (D2) and serotonin type 2 (5-HT2) receptors. Alpha blocker.
This drug is not approved for the treatment of patients with dementia-related psychosis. Prolongs QT interval; caution with other drugs/conditions that increase QTc. Not recommended in hepatic impairment. Risk of neuroleptic malignant syndrome and extrapyramidal symptoms. May cause anticholinergic side effects (eg., confusion, agitation). Blood dyscrasias (leukopenia, neutropenia, agranulocytosis) may occur. Orthostatic hypotension may occur. Lactation: not known if excreted in breast milk, do not nurse
>10% Dizziness (20%), Dry mouth (15%), Nausea (10%), Somnolence (10%), Tachycardia (12%) 1-10% (selected) Diarrhea, Ejaculation failure, Myalgia, Nasal congestion, Orthostatic hypotension, Palpitations, Urinary incontinence, Weight gain Frequency Not Defined (selected) Priapism